IP Library Granted Patent US 12,208,224
Granted Patent B2
US 12,208,224 · App. 17/010,271 · Granted Jan 28, 2025

Chemical ablation and method of treatment for various diseases

Inventors: Lixiao Wang (Henderson, NV); John J. Chen (Plymouth, MN); Yongxing Zhang (Irvine, CA)
Assignee: Neurotronic, Inc.
A61M25/1002A61B18/06A61K31/045A61M5/007A61M5/142A61M5/172A61M25/1011A61M29/02A61B2018/00577A61M2025/105A61M2025/1052A61M2202/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,224
App. No.
17/010,271
Granted
Jan 28, 2025
Kind
B2
Abstract

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Claims (27)

1. A method for treating a body lumen, the method comprising:

inserting a first delivery catheter into a first treatment site in a renal artery, a main renal artery, a renal branch artery, an extra-renal branch artery, a common hepatic artery, a hepatic artery, a hepatic celiac artery, a left hepatic artery, a right hepatic artery, a gastroduodenal artery, a splenic artery, a celiac artery, a gastric artery, right gastric artery, a left gastric artery, a proper hepatic artery, or an esophageal branch artery;

simultaneously infusing a chemical formulation comprising ethanol and having a temperature of 15° C. to 80° C. and/or delivering energy from the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the chemical formulation infused and the energy delivered is effective to injure and damage the tissue at the first treatment site, wherein the chemical formulation provides active cooling and chemical ablation during the energy delivery from the first delivery catheter;

withdrawing the first delivery catheter from the first treatment site;

inserting a second delivery catheter that is the same or different as the first delivery catheter into a second treatment site in a renal artery, a main renal artery, a renal branch artery, an extra-renal branch artery, a common hepatic artery, a hepatic artery, a hepatic celiac artery; a left hepatic artery, a right hepatic artery, a gastroduodenal artery, a splenic artery, a celiac artery, a gastric artery, right gastric artery, a left gastric artery, a proper hepatic artery, or an esophageal branch artery, wherein the second treatment site is a different treatment site than the first treatment site;

simultaneously infusing a chemical formulation comprising ethanol and having a temperature of 15° C. to 80° C. and delivering energy from the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the chemical formulation infused and/or the energy delivered is effective to injure and damage the tissue at the second treatment site, wherein the chemical formulation provides active cooling and chemical ablation during the energy delivery from the second delivery catheter; and

withdrawing the second delivery catheter from the second treatment site;

wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c(A1c), glucose level, body weight, blood pressure, or a combination thereof.

2. The method of claim 1 , wherein the first and/or second delivery catheter is a balloon catheter and the method further comprises:

inflating the first delivery catheter after the insertion to the first treatment site and deflating the first delivery catheter prior to the withdrawing from the first treatment site; and/or

inflating the second delivery catheter after the insertion to the second treatment site and deflating the second delivery catheter prior to the withdrawing from the second treatment site.

3. The method of claim 1 , wherein the chemical formulation comprises one or more ingredients chosen from water, saline, hypertonic saline, phenol, methanol, ethanol, absolute alcohol, isopropanol, propanol, butanol, isobutanol, ethylene glycol, glycerol, acetic acid, lactic acid, propyl iodide, isopropyl iodide, ethyl iodide, methyl acetate, ethyl acetate, ethyl nitrate, isopropyl acetate, ethyl lactate, lipiodol, urea, and derivatives thereof.

4. The method of claim 1 , wherein the chemical formulation comprises ethanol and water, an ethanol/water azeotrope, or ethanol and acetic acid.

5. The method of claim 1 , wherein the chemical formulation is absolute ethanol.

6. The method of claim 1 , wherein the energy is chosen from radiofrequency, microwave, laser, ultrasound, high intensity focused ultrasound, and combinations thereof.

7. The method of claim 1 , wherein the first and/or second delivery catheter comprises a needle catheter or a needle-based catheter.

8. The method of claim 1 , wherein the method is a method of treating diabetes.

9. The method of claim 1 , wherein the method is a method of treating obesity.

10. The method of claim 1 , wherein the method is a method of treating both diabetes and obesity.

11. A method for treating a body lumen, the method comprising:

inserting a first delivery catheter into a first treatment site in a renal artery, a main renal artery, a renal branch artery, an extra-renal branch artery, or a common hepatic artery;

infusing a chemical formulation comprising ethanol and/or delivering energy from the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the chemical formulation infused and/or the energy delivered is effective to injure and/or damage the tissue at the first treatment site;

withdrawing the first delivery catheter from the first treatment site;

inserting a second delivery catheter that is the same or different as the first delivery catheter into a second treatment site in the same artery as the first treatment site;

infusing a chemical formulation comprising ethanol and/or delivering energy from the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the chemical formulation infused and/or the energy delivered is effective to injure and/or damage the tissue at the second treatment site; and

withdrawing the second delivery catheter from the second treatment site;

wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c(A1c), glucose level, body weight, blood pressure, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2020
From: WANG, LIXIAO; CHEN, JOHN J.; ZHANG, YONGXING
To: NEUROTRONIC, INC.
Reel/Frame 053769/0765 →
Continuity (14)
Continuation In Part 16986717 · Aug 6, 2020
Continuation In Part 16563192 · Sep 6, 2019
Continuation 16563213 · Sep 6, 2019
Continuation 16419587 · May 22, 2019
Continuation 16156163 · Oct 10, 2018
Continuation 15521973
Continuation 14438411
Provisional Application 62124868 · Jan 5, 2015
Provisional Application 62122818 · Oct 30, 2014
Provisional Application 61849928 · Feb 5, 2013
Provisional Application 61848483 · Jan 4, 2013
Provisional Application 61797647 · Dec 12, 2012
Provisional Application 61796118 · Nov 2, 2012
Related Publication 20200398032A1 · Dec 24, 2020
References Cited (353)
US 4254056A · Konno et al. · 1981 [cited by applicant]
US 4573966A · Weikl et al. · 1986 [cited by applicant]
US 4653438A · Russell · 1987 [cited by applicant]
US 5045061A · Seifert et al. · 1991 [cited by applicant]
US 5263931A · Miller · 1993 [cited by applicant]
US 5314443A · Rudnick · 1994 [cited by applicant]
US 5315992A · Dalton · 1994 [cited by applicant]
US 5380284A · Don · 1995 [cited by applicant]
US 5419763A · Hildebrand · 1995 [cited by applicant]
US 5423755A · Kesten et al. · 1995 [cited by applicant]
US 5460610A · Don · 1995 [cited by applicant]
US 5599307A · Bacher et al. · 1997 [cited by applicant]
US 5681281A · Vigil et al. · 1997 [cited by applicant]
US 5720735A · Dorros · 1998 [cited by applicant]
US 6048332A · Duffy et al. · 2000 [cited by applicant]
US 6062223A · Palazzo et al. · 2000 [cited by applicant]
US 6135981A · Dyke · 2000 [cited by applicant]
US 6148222A · Ramsey · 2000 [cited by applicant]
US 6258087B1 · Edwards et al. · 2001 [cited by applicant]
US 6623452B2 · Chien et al. · 2003 [cited by applicant]
US 6685672B1 · Forman · 2004 [cited by applicant]
US 7617005B2 · Demarais et al. · 2009 [cited by applicant]
US 7653438B2 · Deem et al. · 2010 [cited by applicant]
US 7717948B2 · Demarais et al. · 2010 [cited by applicant]
US 8052668B2 · Sih · 2011 [cited by applicant]
US 8372054B2 · Duffy et al. · 2013 [cited by applicant]
US 8740849B1 · Fischell · 2014 [cited by examiner]
US 8774913B2 · Demarais et al. · 2014 [cited by applicant]
US 8840601B2 · Salahieh et al. · 2014 [cited by applicant]
US 9114123B2 · Vafai et al. · 2015 [cited by applicant]
US 10286191B2 · Wang et al. · 2019 [cited by applicant]
US 10537375B2 · Wang · 2020 [cited by applicant]
US 10758713B2 · Wang et al. · 2020 [cited by applicant]
US 11382689B2 · Wang · 2022 [cited by applicant]
US 11517725B2 · Wang et al. · 2022 [cited by applicant]
US 11648378B2 · Wang et al. · 2023 [cited by applicant]
US 11684417B2 · Wang · 2023 [cited by applicant]
US 12005207B2 · Wang · 2024 [cited by examiner]
US 20020014238A1 · Kotmel · 2002 [cited by applicant]
US 20020068953A1 · Kokish · 2002 [cited by applicant]
US 20020177846A1 · Mulier · 2002 [cited by applicant]
US 20030066532A1 · Gobel · 2003 [cited by applicant]
US 20040267336A1 · Morrison et al. · 2004 [cited by applicant]
US 20050288639A1 · Hibner · 2005 [cited by applicant]
US 20060161233A1 · Barry et al. · 2006 [cited by applicant]
US 20060235474A1 · Demarais · 2006 [cited by applicant]
US 20060265014A1 · Demarais et al. · 2006 [cited by applicant]
US 20060282120A1 · Sih · 2006 [cited by applicant]
US 20070077230A1 · Mon · 2007 [cited by applicant]
US 20080114297A1 · Barry et al. · 2008 [cited by applicant]
US 20080118544A1 · Wang · 2008 [cited by applicant]
US 20080208118A1 · Goldman · 2008 [cited by applicant]
US 20080255508A1 · Wang · 2008 [cited by applicant]
US 20080255509A1 · Wang · 2008 [cited by applicant]
US 20090192505A1 · Askew et al. · 2009 [cited by applicant]
US 20090301483A1 · Barry et al. · 2009 [cited by applicant]
US 20100010470A1 · Bates · 2010 [cited by applicant]
US 20100087781A1 · Adams et al. · 2010 [cited by applicant]
US 20100145304A1 · Cressman · 2010 [cited by applicant]
US 20100209472A1 · Wang · 2010 [cited by applicant]
US 20110104061A1 · Seward · 2011 [cited by applicant]
US 20110152683A1 · Gerrans et al. · 2011 [cited by applicant]
US 20110182912A1 · Evans et al. · 2011 [cited by applicant]
US 20110218564A1 · Drasler et al. · 2011 [cited by applicant]
US 20120083809A1 · Drasler et al. · 2012 [cited by applicant]
US 20120116438A1 · Salahieh et al. · 2012 [cited by applicant]
US 20120197245A1 · Burnett et al. · 2012 [cited by applicant]
US 20120209251A1 · Bates · 2012 [cited by applicant]
US 20120215212A1 · Selzer et al. · 2012 [cited by applicant]
US 20120259269A1 · Meyer · 2012 [cited by applicant]
US 20120271277A1 · Fischell et al. · 2012 [cited by applicant]
US 20120271301A1 · Fischell et al. · 2012 [cited by applicant]
US 20130138082A1 · Salahieh · 2013 [cited by examiner]
US 20130178910A1 · Azamian · 2013 [cited by examiner]
US 20130189190A1 · Wang · 2013 [cited by applicant]
US 20150056298A1 · Azamian et al. · 2015 [cited by applicant]
US 20150272666A1 · Wang · 2015 [cited by applicant]
US 20160135879A1 · Beasley et al. · 2016 [cited by applicant]
US 20160310200A1 · Wang · 2016 [cited by applicant]
US 20180015264A1 · Wang et al. · 2018 [cited by applicant]
US 20190015639A1 · Wang et al. · 2019 [cited by applicant]
US 20190038881A1 · Wang et al. · 2019 [cited by applicant]
US 20190307507A1 · Wang · 2019 [cited by applicant]
US 20190388147A1 · Wang · 2019 [cited by applicant]
US 20200009355A1 · Wang et al. · 2020 [cited by applicant]
US 20200016379A1 · Wang et al. · 2020 [cited by applicant]
US 20200086093A1 · Wang · 2020 [cited by applicant]
US 20200360671A1 · Wang et al. · 2020 [cited by applicant]
US 20210275784A1 · Wang · 2021 [cited by applicant]
US 20210275785A1 · Wang · 2021 [cited by applicant]
US 20210275786A1 · Wang · 2021 [cited by applicant]
US 20210275787A1 · Wang · 2021 [cited by applicant]
US 20220233827A1 · Wang et al. · 2022 [cited by applicant]
US 20230270489A1 · Wang · 2023 [cited by applicant]
US 20240277976A1 · Wang et al. · 2024 [cited by applicant]
US 20240277977A1 · Wang et al. · 2024 [cited by applicant]
CN 1593359A · 2005 [cited by applicant]
CN 101035593 · 2007 [cited by applicant]
CN 101861184A · 2010 [cited by applicant]
CN 102481428A · 2012 [cited by applicant]
CN 102573466 · 2012 [cited by applicant]
CN 102600546A · 2012 [cited by applicant]
CN 102698354A · 2012 [cited by applicant]
CN 102727986A · 2012 [cited by applicant]
CN 102743163A · 2012 [cited by applicant]
CN 107106820A · 2017 [cited by applicant]
CN 110772311A · 2020 [cited by applicant]
CN 113040895 · 2021 [cited by applicant]
CN 118555975 · 2024 [cited by applicant]
EP 2497524A1 · 2012 [cited by applicant]
EP 2914326 · 2023 [cited by applicant]
JP S5769814 · 1982 [cited by applicant]
JP H04215767A · 1992 [cited by applicant]
JP H07308382A · 1995 [cited by applicant]
JP 08508917A · 1996 [cited by applicant]
JP 2000279524 · 2000 [cited by applicant]
JP 2004035128 · 2004 [cited by applicant]
JP 2004180892A · 2004 [cited by applicant]
JP 2004528924A · 2004 [cited by applicant]
JP 2005506101A · 2005 [cited by applicant]
JP 2006502801A · 2006 [cited by applicant]
JP 2010078379A · 2010 [cited by applicant]
JP 2010519005A · 2010 [cited by applicant]
JP 2010528815A · 2010 [cited by applicant]
JP 2011519699A · 2011 [cited by applicant]
JP 2012505050A · 2012 [cited by applicant]
JP 2012508067A · 2012 [cited by applicant]
JP 2012517858A · 2012 [cited by applicant]
JP 2012524808A · 2012 [cited by applicant]
JP 2013517847A · 2013 [cited by applicant]
JP 2014524342A · 2014 [cited by applicant]
JP 2014527272A · 2014 [cited by applicant]
JP 2015536945 · 2015 [cited by applicant]
JP 2017533036A · 2017 [cited by applicant]
JP 6389185B2 · 2018 [cited by applicant]
JP 2018153239 · 2018 [cited by applicant]
JP 2020189858 · 2020 [cited by applicant]
JP 2021046397 · 2021 [cited by applicant]
JP 2023027052 · 2023 [cited by applicant]
WO WO9421320A1 · 1994 [cited by applicant]
WO WO9618427A1 · 1996 [cited by applicant]
WO WO9717099A1 · 1997 [cited by applicant]
WO WO0119445A1 · 2001 [cited by applicant]
WO WO02051490A1 · 2002 [cited by applicant]
WO WO2006055695A1 · 2006 [cited by applicant]
WO WO2008106357A1 · 2008 [cited by applicant]
WO WO2009076732A1 · 2009 [cited by applicant]
WO WO2009082433A2 · 2009 [cited by applicant]
WO WO2010033686A1 · 2010 [cited by applicant]
WO WO2010124120A1 · 2010 [cited by applicant]
WO WO2011094367A1 · 2011 [cited by applicant]
WO WO2011119159A1 · 2011 [cited by applicant]
WO WO2013026565A1 · 2013 [cited by applicant]
WO WO2013028781A1 · 2013 [cited by applicant]
WO 2013067382 · 2013 [cited by applicant]
WO WO2013090848A1 · 2013 [cited by applicant]
WO WO2014070820A2 · 2014 [cited by applicant]
WO 2015058296 · 2015 [cited by applicant]
WO WO2016070032A1 · 2016 [cited by applicant]
WO 2023091475 · 2023 [cited by applicant]
Results of related clinical study described in Declaration under 37 C.F.R. section 1.132 filed in U.S. Appl. No. 16/986,717. This application is a continuation in part (CIP) of U.S. Appl. No. 16/986,717. (Year: 2024). [cited by examiner]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Jan. 28, 2022”, 10 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 4 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed May 20, 2022”, w / English translation, 16 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Examiners Decision of Final Refusal mailed Jun. 21, 2022”, w / English translation, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 5, 22 to Non Final Office Action mailed Apr. 5, 2022”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 13, 23 to Final Office Action mailed May 15, 2023”, 19 pgs. [cited by applicant]
“European Application Serial No. 23183741.0, Extended European Search Report mailed Jul. 21, 2023”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Advisory Action mailed Jul. 26, 2023”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Aug. 9, 2023 to Non Final Office Action mailed May 31, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Aug. 24, 2023”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,765, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,795, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,823, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Refusal mailed Jul. 6, 2021”, w English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Aug. 17, 2021”, w English Translation, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Notification of Reasons for Refusal mailed Sep. 28, 2021”, w English Translation, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed Sep. 30, 2021”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Oct. 23, 20 to Office Action mailed Jun. 23, 2020”, w English Claims, 14 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Response filed Oct. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Nov. 24, 2020 to Office Action mailed Jul. 2, 2020”, w English Claims, 16 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response field Dec. 21, 2022 to Office Action mailed Nov. 22, 2022”, w English Translation, 11 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Preliminary Examination Report mailed Jan. 24, 2023”, w English Translation, 2 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Aug. 10, 2022 to Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 52 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowance mailed Feb. 3, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Feb. 6, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,192, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 30, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowability mailed Mar. 1, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Restriction Requirement mailed Mar. 2, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,192, Notice of Allowance mailed Mar. 8, 2023”, 8 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Feb. 27, 2023 to Office Action mailed Oct. 18, 2022”, w English Claims, 8 pgs. [cited by applicant]
“International Application Serial No. PCT US2022 050087, International Search Report mailed Mar. 1, 2023”, 3 pgs. [cited by applicant]
“International Application Serial No. PCT US2022 050087, Written Opinion mailed Mar. 1, 2023”, 4 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Decision of Rejection mailed Mar. 14, 2023”, w English translation, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Jan. 25, 2024 to Final Office Action mailed Nov. 1, 2023”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Response filed Jan. 30, 2024 to Notification of Reasons for Rejection mailed Oct. 31, 2023”, w English Claims, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Notice of Allowance mailed Feb. 14, 2024”, 8 pgs. [cited by applicant]
“European Application Serial No. 23183741.0, Response filed Feb. 19, 2024 to Extended European Search Report mailed Jul. 21, 2023”, 12 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Feb. 27, 2024 to Notification of Reasons for Refusal mailed Nov. 11, 2023”, w english claims, 9 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Non Final Office Action mailed Apr. 12, 2024”, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed May 6, 2024 to Office Action mailed Dec. 22, 2023”, w current English claims, 15 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Examiners Decision of Final Refusal mailed May 14, 2024”, W English Translation, 4 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Rejection mailed May 14, 2024”, W English Translation, 25 pgs. [cited by applicant]
“Recording of clinical analysis research association”, No. 5, [Online] Retrieved from the internet:http: www.jrsca.jp contents records contents Pdf 5-PDF?, (Feb. 2005), 3 pgs. [cited by applicant]
Sugimoto, Ayurni, “Nervous Control of Glucose Metabolism in the Liver”, Lifestyle Research vol. 3, No. 1,, (2001), 138-141. [cited by applicant]
“U.S. Appl. No. 17/329,842, Restriction Requirement mailed Oct. 17, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Final Office Action mailed Nov. 1, 2023”, 16 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Notification of Reasons for Rejection mailed Oct. 31, 2023”, W English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Nov. 11, 2023”, w English Translation, 10 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Dec. 22, 2023”, w English Translation, 8 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Advisory Action mailed Apr. 30, 2019”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed Feb. 25, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed May 9, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Sep. 21, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Oct. 20, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Jan. 17, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Apr. 16, 2019 to Final Office Action mailed Feb. 25, 2019”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 7, 2018 to Final Office Action mailed May 9, 2018”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 25, 2017 to Restriction Requirement mailed Jul. 14, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Oct. 8, 2018 to Non Final Office Action mailed Sep. 21, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Restriction Requirement mailed Jul. 14, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Advisory Action mailed Jul. 30, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Corrected Notice of Allowability mailed Nov. 20, 2019”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed May 3, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed Aug. 16, 2018”, 26 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Feb. 15, 2018”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Nov. 30, 2018”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Notice of Allowance mailed Oct. 1, 2019”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Preliminary Amendment filed Apr. 20, 2016”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Mar. 20, 2019 to Non Final Office Action mailed Nov. 30, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jun. 14, 2018 to Non Final Office Action mailed Feb. 15, 2018”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jul. 1, 2019 to Final Office Action mailed May 3, 2019”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Oct. 26, 2018 to Final Office Action mailed Aug. 16, 2018”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Dec. 27, 2017 to Restriction Requirement mailed Oct. 31, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Restriction Requirement mailed Oct. 31, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Examiner Interview Summary mailed Jun. 4, 2018”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Final Office Action mailed Jan. 15, 2019”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed May 18, 2018”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed Sep. 14, 2018”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Notice of Allowance mailed Mar. 27, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Preliminary Amendment filed Apr. 26, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Mar. 14, 2019 to Final Office Action mailed Jan. 15, 2019”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Dec. 10, 2018 to Non Final Office Action mailed Sep. 14, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Non Final Office Action mailed Apr. 2, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Notice of Allowance mailed Jul. 22, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Response filed Jul. 1, 2020 to Non Final Office Action mailed Apr. 2, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Preliminary Amendment filed Jul. 9, 2019”, 3 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Jan. 17, 2018”, (English Translation), 8 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Feb. 19, 2019”, W/ English Translation, 6 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed May 19, 2017”, W/ English Translation, 18 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Dec. 27, 2019”, w/ English translation, 12 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Apr. 2, 2018 to Office Action mailed Jan. 17, 2018”, w/ English claims, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Aug. 23, 2019 to Office Action mailed Feb. 19, 2019”, w/English Claims, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Oct. 9, 2017 to Office Action mailed May 19, 2017”, w/ English Claims, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed 11-27-8 to Office Action mailed”, w/English Claims, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Jul. 2, 2020”, w/English translation, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Sep. 3, 2019”, W/English Translation, 17 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Mar. 18, 2020 to Office Action mailed Sep. 3, 2019”, w/English Claims, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Voluntary Amendment mailed Feb. 22, 2018”, w/English Claims, 21 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 7 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Jun. 1, 2018”, 9 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Extended European Search Report mailed Jun. 6, 2016”, 6 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Office Action mailed Jun. 12, 2015”, 3 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Jul. 20, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 13 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Oct. 19, 2015 to Office Action mailed Jun. 12, 2015”, 13 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Dec. 1, 2016 to Extended European Search Report mailed Jun. 6, 2016”, 20 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 8 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Extended European Search Report mailed May 30, 2018”, 15 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Reponse filed Nov. 12, 2018 to Extended European Search Report mailed May 30, 2018”, 17 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Preliminary Report on Patentability mailed May 11, 2017”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Search Report mailed Jan. 21, 2016”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, Written Opinion mailed Jan. 21, 2016”, 7 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Jul. 4, 2017”, w/English Translation, 12 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Dec. 29, 2017”, With English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Mar. 16, 2018 to Office Action mailed Dec. 29, 2017”, w/ English Claims, 11 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Oct. 4, 2017 to Office Action mailed Jul. 4, 2017”, w/ English Claims, 19 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/ English Translation, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Office Action mailed Jun. 23, 2020”, w/ English translation, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Mar. 6, 2020 to Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/English Claims, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Examiners Decision of Final Refusal mailed Apr. 7, 2020”, w/ English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jul. 2, 2019”, W/ English Translation, 16 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Oct. 1, 2019 to Notification of Reasons for Refusal mailed Jul. 2, 2019”, w/English Claims, 10 pgs. [cited by applicant]
Krum, H., et aI., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.”, Lancet, 373(9671), (2009), 2375-1281. [cited by applicant]
U.S. Appl. No. 17/719,032, filed Apr. 12, 2022, Chemical Ablation and Method of Treatment for Various Diseases. [cited by applicant]
U.S. Appl. No. 17/329,765, filed May 25, 2021, Method of Treatment for Various Diseases. [cited by applicant]
U.S. Appl. No. 17/329,795, filed May 25, 2021, Method of Treatment for Various Diseases. [cited by applicant]
U.S. Appl. No. 17/329,823, filed May 25, 2021, Method of Treatment for Various Diseases. [cited by applicant]
U.S. Appl. No. 17/329,842, filed May 25, 2021, Method of Treatment for Various Diseases. [cited by applicant]
U.S. Appl. No. 14/438,411, filed Apr. 24, 2015, Chemical Ablation Formulations and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/419,587, filed May 22, 2019, Chemical Ablation Formulations and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/563,192, filed Sep. 6, 2019, Chemical Ablation Formulations and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 15/521,973 U.S. Pat. No. 10,286,191, filed Apr. 26, 2017, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/156,163 U.S. Pat. No. 10,758,713, filed Oct. 10, 2018, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/563,213, filed Sep. 6, 2019, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/986,717, filed Aug. 6, 2020, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 15/133,976 U.S. Pat. No. 10,537,375, filed Apr. 20, 2016, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/563,235, filed Sep. 6, 2019, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
U.S. Appl. No. 16/690,992, filed Nov. 21, 2019, Chemical Ablation and Methods of Treatments for Various Diseases. [cited by applicant]
“Japanese Application Serial No. 202080044525.9, Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w English Translation, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed Jul. 26, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Aug. 11, 2022 to Non Final Office Action mailed May 12, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Aug. 26, 2022”, 7 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Response filed Sep. 2, 2022 to Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 116 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Non Final Office Action mailed Sep. 15, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Feb. 11, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Final Office Action mailed Feb. 24, 2022”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Mar. 9, 2022 to Final Office Action mailed Feb. 24, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Apr. 5, 2022”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Notice of Allowance mailed Apr. 11, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Corrected Notice of Allowability mailed Apr. 27, 2022”, 5 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Response filed Mar. 28, 2022 to Notification of Reasons for Refusal mailed Sep. 28, 2021”, w out English claims, Claims not amended in filed response, 21 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w out English claims, Claims not amended in response filed, 5 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w o English Claims, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed May 12, 2022”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Apr. 18, 2023 to Non Final Office Action mailed Feb. 6, 2023”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Apr. 19, 2023 to Restriction Requirement mailed Mar. 2, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed May 15, 2023”, 26 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Non Final Office Action mailed May 31, 2023”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Voluntary Amendment filed Jun. 19, 2023”, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Jun. 28, 2023 to Decision of Rejection mailed Mar. 14, 2023”, w English Claims, 13 pgs. [cited by applicant]
Tian, Juanhua, “Rectifying disorder of extracellularmatrix to suppress urethral stricture by protein nanofilm-controlled drug delivery from urinary catheter”, nature communications, (5 17 2023), 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Non Final Office Action mailed Oct. 5, 2021”, 15 pgs. [cited by applicant]
“Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma”, A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial Am J Respir Crit Care Med vol. 181., (2010), 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Nov. 4, 2021 to Non Final Office Action mailed Oct. 5, 2021”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Nov. 16, 2021 to Non Final Office Action mailed Sep. 30, 2021”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Nov. 16, 2021 to Notification of Reasons for Refusal mailed Aug. 17, 2021”, w Engilsh Claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English Translation, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English Translation, 8 pgs. [cited by applicant]
Dunican, Eleanor M, “Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction”, J Clin Invest. 2018;128(3), (2018), 14 pgs. [cited by applicant]
Greer, M, “Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation”, American Journal of Transplantation 2014 14: 2400-2405, (2014), 2400-2405. [cited by applicant]
Kim, K. C., “Airway goblet cell mucin: its structure and regulation of secretion”, Series Airway Mucus Eur Respir J 1997; 10:, (1997), pp. 2644-2649. [cited by applicant]
Krmisky, William, “Thermal ablation for asthma: current status and technique”, J Thorac Dis 2017;9(Suppl 2):S104-S109, (2017), 6 pgs. [cited by applicant]
Menzella, Francesco, “Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights”, Journal of Asthma and Allergy 2020:13, (2020), 13 pgs. [cited by applicant]
Peters, Michael C, “Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency”, Am J Respir Crit Care Med vol. 202, Iss 7, (2020), 10 pgs. [cited by applicant]
Sakata, Kenneth K, “Paclitaxel-coated balloon dilation for central airway obstruction”, Respiratory Medicine Case Reports 24, (2018), 129-132. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Sep. 28, 2022 to Office Action mailed May 20, 2022”, w English Claims, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Oct. 26, 2022 to Final Office Action mailed Jul. 26, 2022”, 12 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Invitation pursuant to Article 94(3) and Rule 71(1) EPC mailed Oct. 11, 2022”, 4 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed Oct. 18, 2022”, w English translation, 7 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Office Action mailed Nov. 8, 2022”, w English Translation, 45 pgs. [cited by applicant]
“Japanese Application Serial No. 202080044525.9, Response filed Nov. 7, 2022 to Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w English Claims, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/563, 192, Non Final Office Action mailed Nov. 30, 2022”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Response filed Dec. 13, 2022 to Non Final Office Action mailed Sep. 15, 2022”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2022/050087, International Preliminary Report on Patentability mailed May 30, 2024”, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Jun. 4, 2024”, w/ English translation, 6 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Response filed Jul. 2, 2024 to Non Final Office Action mailed Apr. 12, 2024”, 11 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Jul. 10, 2024”, w English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Aug. 13, 2024 to Notification of Reasons for Rejection mailed May 14, 2024”, W English Claims, 9 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Notice of Allowance mailed Aug. 22, 2024”, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Sep. 3, 2024 to Notification of Reasons for Refusal mailed Jun. 4, 2024”, w English Claims, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed Sep. 10, 2024 to Office Action mailed Jul. 10, 2024”, w current English claims, 19 pgs. [cited by applicant]
Cited By (4)
US 12,685,846 US 12,691,260 US 12,691,262 US 12,714,834